tadalafil has been researched along with lenalidomide in 4 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 3,532 | 725 | 2,850 |
| Protein | Taxonomy | tadalafil (IC50) | lenalidomide (IC50) |
|---|---|---|---|
| Bromodomain-containing protein 4 | Homo sapiens (human) | 5.19 | |
| DNA damage-binding protein 1 | Homo sapiens (human) | 1.5953 | |
| Protein cereblon | Homo sapiens (human) | 1.6572 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Borrello, I; Bui, M; Ghosh, N; Noonan, KA; Rudraraju, L | 1 |
| Hountras, P; Lane, T | 1 |
1 review(s) available for tadalafil and lenalidomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for tadalafil and lenalidomide
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbolines; Clarithromycin; Dexamethasone; Humans; Immune Tolerance; Immunologic Factors; Interleukin-4 Receptor alpha Subunit; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloid Cells; Phosphodiesterase 5 Inhibitors; T-Lymphocytes; Tadalafil; Thalidomide | 2014 |
A 65-Year-Old Man With Weight Loss, Peripheral Neuropathy, and Lower Extremity Swelling.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Edema; Exercise Tolerance; Humans; Hypertension, Pulmonary; Lenalidomide; Male; Neoplasms, Plasma Cell; Peripheral Nervous System Diseases; Phosphodiesterase 5 Inhibitors; POEMS Syndrome; Positron Emission Tomography Computed Tomography; Stem Cell Transplantation; Syncope; Tadalafil; Weight Loss | 2022 |